Neuropathic Pain Market Poised for Significant Growth, Reaching $13.3 Billion by 2032
The global neuropathic pain market, valued at $7.7 billion in 2022, is projected to expand at a CAGR of 5.6%, reaching $13.3 billion by 2032. This growth is fueled by increasing demand for neuropathic pain medications, rising awareness campaigns, and a surge in clinical trials for innovative treatments. Notably, Algiax Pharmaceuticals advanced its Phase 2a study for AP-325 in May 2023, showcasing the market's potential for groundbreaking therapies.
Comments
Post a Comment